Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $138.65 USD
Change Today 0.00 / 0.00%
Volume 0.0
TMO On Other Exchanges
Symbol
Exchange
New York
Stuttgart
Mexico
As of 8:04 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

thermo fisher scientific inc (TMO) Snapshot

Open
$138.73
Previous Close
$137.02
Day High
$139.12
Day Low
$137.45
52 Week High
07/22/15 - $141.25
52 Week Low
10/15/14 - $107.33
Market Cap
55.2B
Average Volume 10 Days
1.8M
EPS TTM
$4.21
Shares Outstanding
398.1M
EX-Date
09/11/15
P/E TM
32.9x
Dividend
$0.60
Dividend Yield
0.43%
Current Stock Chart for THERMO FISHER SCIENTIFIC INC (TMO)

thermo fisher scientific inc (TMO) Details

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables used in biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases. This segment serves pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for applications in the laboratory, on the production line, and in the field. It serves pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as the clinical laboratory. The company’s Specialty Diagnostics segment offers liquid, ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, and calibration verification fluids; blood-test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; and human leukocyte antigen typing and testing for the organ transplant market. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratory customers. Its Laboratory Products and Services segment offers sample preparation and preservation equipment, cold storage equipment, centrifugation products, biological safety cabinets, temperature control products, water analysis instruments, and other laboratory equipment, as well as laboratory consumables, research and safety market solutions, and biopharma services. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

50,000 Employees
Last Reported Date: 07/22/15
Founded in 1956

thermo fisher scientific inc (TMO) Top Compensated Officers

Chief Executive Officer, President, Director,...
Total Annual Compensation: $1.3M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $674.0K
Executive Vice President and President of Lif...
Total Annual Compensation: $723.1K
Executive Vice President and President of Lab...
Total Annual Compensation: $716.2K
Senior Vice President and President of Analyt...
Total Annual Compensation: $568.1K
Compensation as of Fiscal Year 2014.

thermo fisher scientific inc (TMO) Key Developments

Thermo Fisher Scientific Unveils New Solutions to Advance the Use of Clinical Testing and Improve Patient Outcomes

Thermo Fisher Scientific, Inc. introduced new instruments and assays to expand the use of clinical testing, enhance laboratory productivity and ultimately improve patient outcomes. The new solutions were unveiled at the 2015 AACC Annual Meeting and Clinical Lab Expo, Booth 3135, being held at the Georgia World Congress Center in Atlanta, July 26 - 30. For laboratories performing allergy and autoimmunity testing, the fully automated Thermo Scientific Phadia 2500E Laboratory System analyzes up to 25,000 samples per week, enabling clinical labs to deliver patient test results quickly and accurately. These Phadia Laboratory Systems detect and quantify relevant antibodies in blood samples to identify possible allergy or autoimmune sensitivity. The company’s portfolio of allergy test kits has been expanded to include ImmunoCAP Allergen Components for Hazelnut, Walnut andCashew Nut to better identify patients who may have potentially serious reactions to a wider variety of food products. Thermo Fisher has also introduced new immunoassays with FDA 510(k) clearance for the detection of autoimmune disorders. These include the EliA PR3, EliA MPO andEliA GBM Assays, which measure auto-antibodies for the diagnosis of ANCA Vasculitis, Goodpasture Syndrome and associated conditions that typically result in kidney disease. All of these conditions exhibit very similar symptoms, and the new tests allow for a specific diagnosis, allowing clinicians to develop a better-informed patient treatment strategy.

Thermo Fisher Scientific, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 27, 2015; Revises Earnings Guidance for the Full Year of Fiscal 2015

Thermo Fisher Scientific, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 27, 2015. For the quarter, the company reported revenues of $4,270.9 million against $4,321.9 million a year ago. Operating income was $595.8 million against $348.1 million a year ago. Income before income taxes was $503.6 million against $236.5 million a year ago. Net income was $511.6 million or $1.27 per diluted share against $278.5 million or $0.69 per diluted share a year ago. Adjusted operating income was $950.3 million against $923.6 million a year ago. Adjusted net income was $738.5 million or $1.84 per share against $695.1 million or $1.72 per share a year ago. GAAP net cash provided by operating activities was $764.9 million against $888.7 million a year ago. Purchases of property, plant and equipment were $95.3 million against $75.5 million a year ago. Free cash flow was $677.4 million against $823.4 million a year ago. For the six months period, the company reported revenues of $8,189.7 million against $8,225.4 million a year ago. Operating income was $1,083.1 million against $1,223.6 million a year ago. Income before income taxes was $885.6 million against $1,010.9 million a year ago. Net income was $896.7 million or $2.23 per diluted share against $821.6 million or $2.05 per diluted share a year ago. Adjusted operating income was $1,806.9 million against $1,754.1 million a year ago. Adjusted net income was $1,394.1 million or $3.47 per diluted share against $1,305.9 million or $3.26 per diluted share a year ago. GAAP net cash provided by operating activities was $844.9 million against $989.9 million a year ago. Purchases of property, plant and equipment were $192.5 million against $180.2 million a year ago. Free cash flow was $662.9 million against $824.3 million a year ago. The company is raising its full-year 2015 revenue and adjusted EPS guidance to reflect current foreign currency exchange rates and strong operating performance. The company now expects revenue for 2015 to be in the range of $16.72 to $16.86 billion, versus its previous guidance of $16.67 to $16.83 billion. The company is also raising adjusted EPS guidance to a new range of $7.28 to $7.41 from the $7.25 to $7.40 previously announced, for 5% to 6% growth over 2014. The 2015 guidance does not include the acquisition of Alfa Aesar or any future acquisitions or divestitures and is based on current foreign exchange rates. The company is expecting net capital expenditures to be in the range of $435 million to $450 million, unchanged from its previous guidance. The company is still expecting about $2.6 billion of free cash flow for full year 2015, consistent with previous guidance. Moving below the line, the company is still expecting net interest expense to be in the range of $375 million to $385 million. The company is forecasting adjusted income tax rate to be about 14%, consistent with its previous guidance.

Thermo Fisher Scientific Introduces PrioCHECK Trichinella AAd to Test Swine Carcasses for Trichinella

Thermo Fisher Scientific Introduced PrioCHECK Trichinella AAD. Abattoirs and meat packers have a cleaner, safer way to test swine carcasses for potentially dangerous Trichinella at meat inspection – new PrioCHECK Trichinella AAD. The alternative artificial digestion (AAD) method has been validated and approved by the European Union and is listed in commission regulation (EC) 2075/2005. PrioCHECK Trichinella AAD is a reliable alternative to the currently used pepsin-based artificial digestion method, because the test uses a recombinantly produced enzyme from a standardized and secured production facility, ensuring good availability of the enzyme and consistent quality. In addition, it does not use pepsin powder or hydrochloric acid, increasing ease of handling and worker safety. The Community Reference Laboratory (CRL) for Trichinella in Rome has extensively validated the performance of the PrioCHECK Trichinella AAD Kit and has approved the product as an official method for use in the in vitro detection of Trichinella spp. in meat of domestic swine.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TMO:US $138.65 USD 0.00

TMO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.94 USD 0.00
Biogen Inc $319.93 USD 0.00
Danaher Corp $88.40 USD 0.00
Safran SA €61.13 EUR +0.15
Syngenta AG SFr.393.50 CHF +3.40
View Industry Companies
 

Industry Analysis

TMO

Industry Average

Valuation TMO Industry Range
Price/Earnings 28.0x
Price/Sales 3.2x
Price/Book 2.6x
Price/Cash Flow 27.3x
TEV/Sales 2.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERMO FISHER SCIENTIFIC INC, please visit www.thermofisher.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.